STACKD Research is educational—not medical advice. Disclaimer
Also known as: CJC-1295 DAC · Modified GRF 1-29
A growth hormone–releasing hormone (GHRH) analogue discussed for GH-axis support. Often mentioned with ipamorelin in fitness forums as a commonly discussed pairing.
Stimulates pituitary GH release via GHRH receptor pathways. DAC variants prolong half-life; non-DAC (Mod GRF) versions are shorter-acting—labels online are frequently imprecise.
Some human pharmacokinetic and GH-response data exist for CJC-1295 constructs. Broader physique and recovery claims largely rely on GH physiology rather than large outcome trials in healthy athletes.
GH elevation carries theoretical risks (edema, insulin resistance, IGF-1 elevation). Compound identity (DAC vs non-DAC) is often unclear in gray-market products. Not a substitute for clinical GH deficiency care.
Start with our in-house roundups—plain-language synthesis of the research, with primary sources cited at the bottom of each.
Secondary citations for verification. Prefer the STACKD summary above for context before opening these.
2006 · human
Human data on sustained GH and IGF-I elevation after CJC-1295.
Commonly discussed together
Fitness discussions often group a GHRH analogue (CJC-1295 / Mod GRF) with ipamorelin when talking about GH-axis pulses, sleep, and recovery themes.
Pairing popularity is not evidence of synergy from large RCTs. Confirm peptide identity (e.g., DAC vs non-DAC) in any primary literature you review.
Muscle / GH axis · Sleep / recovery adjunct · Recovery